{"name":"Seung-Whan Lee, M.D., Ph.D.","slug":"seung-whan-lee-m-d-ph-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"low-intensity statin plus ezetimibe","genericName":"low-intensity statin plus ezetimibe","slug":"low-intensity-statin-plus-ezetimibe","indication":"Hypercholesterolemia and dyslipidemia management","status":"marketed"}]}],"pipeline":[{"name":"low-intensity statin plus ezetimibe","genericName":"low-intensity statin plus ezetimibe","slug":"low-intensity-statin-plus-ezetimibe","phase":"marketed","mechanism":"A combination therapy that reduces LDL cholesterol through dual inhibition of cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe).","indications":["Hypercholesterolemia and dyslipidemia management","Cardiovascular risk reduction in patients requiring LDL cholesterol lowering"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}